NCT06854003 2026-02-20
BRAZAN
Dana-Farber Cancer Institute
Phase 2 Recruiting
Clinical Trials
5 trialsNCT06563596 2026-02-19
Epco, Zanu, Ritux for R/R FL or MZL
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06563505 2026-01-21
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07052695 2025-12-15
Mosunetuzumab for CLL MRD Clearance
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06520098 2025-10-14
Benefit VA
VA Office of Research and Development
Phase 2 Recruiting